Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz

HIV Medicine

Volumn 4, Issue 1, 2003, Pages 62-66

  Lochet, P ^a   Peyriere H ^b   Lotthe A ^a   Mauboussin, J M ^c   Delmas, B ^d   Reynes, J ^a  

^a GUI DE CHAULIAC HOSPITAL   (France)

^b LAPEYRONIE HOSPITAL   (France)

^c NÎMES UNIVERSITY HOSPITAL   (France)

^d Perpignan Hospital   (France)

Author keywords

Adverse reactions; Depression; Efavirenz; Neuropsychiatric; Quality of life

Indexed keywords

EFAVIRENZ; PROTEINASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; OXAZINE DERIVATIVE;

ADULT; AGED; AGGRESSIVENESS; ANXIETY DISORDER; ARTICLE; BEHAVIOR DISORDER; COGNITIVE DEFECT; CONCENTRATION LOSS; CONTROLLED STUDY; DATA ANALYSIS; DISEASE SEVERITY; DREAM; DROWSINESS; DRUNKENNESS; EMOTIONAL DISORDER; EUPHORIA; FATIGUE; FEMALE; HALLUCINATION; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MOOD DISORDER; OUTPATIENT; PERSONALITY DISORDER; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RESTLESSNESS; SEXUAL BEHAVIOR; SIDE EFFECT; SLEEP DISORDER; SUICIDAL BEHAVIOR; VERTIGO; WAKEFULNESS; ADOLESCENT; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DEPRESSION; FOLLOW UP; MENTAL DISEASE; MIDDLE AGED; MULTICENTER STUDY;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; ANXIETY DISORDERS; COGNITION DISORDERS; DEPRESSIVE DISORDER; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; MOOD DISORDERS; OXAZINES; QUALITY OF LIFE; QUESTIONNAIRES; SLEEP DISORDERS;

EID: 0037271311     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.2003.00136.x     Document Type: Article

References (18)

1. Adkins JC, Nobles S. Efavirenz. Drugs 1998; 56: 1055-1066.
2. Producer Information Sustiva. Efavirenz. DuPont Pharmaceuticals, Wilmington, DE, 1998.
3. Gregoire V, Mariot P, Baconnet B. Efficacy and safety of SUSTIVA in the french ATU. a programme providing rapid access to drug prior to registration. 13th International AIDS Conference. Durban, South Africa, July 2000 [Abstract B5272].
4. Ruiz NM, Bessen LJ, Manion DJ et al. Potential adverse experiences associated with efavirenz in adults. 6th Conference on Retroviruses and Opportunistic Infections. Chicago, IL, February 1999 [Abstract 655].
5. Ginisty S, Carlier P, Bourdon JH et al. Assesment of antiretroviral efavirenz tolerability in a follow-up cohort study. Thérapie 2000; 55: 425.
6. American Psychiatric Association. The Diagnostic and Statistical Manual of Mental Disorders, 4th edn. The American Psychiatric Association, Washington DC, 1994
7. Pariente P, Challita H, Mesbah M et al. The GHQ-28 questionnaire in French: a validation survey. Eur Psy 1998; 7: 15-20.
8. Blanch J, Corbella B, Garcia F et al. Manic syndrome associated with efavirenz overdose. Clin Infect Dis 2001; 33: 270-271.
9. Sanz de la Garza CL, Paoletti-Duartes S, Garcia-Martin C et al. Efavirenz induced psychosis. AIDS 2001; 15: 1911-1912.
10. Peyriere H, Mauboussin JM, Rouanet I et al. Management of sudden psychiatric disorders related to efavirenz. AIDS 2001; 15: 1323-1328.
11. Halman M. Management of depression and related neuropsychiatric symptoms associated with HIV/AIDS and antiretroviral therapy. Can J Infect Dis 2001; 12: 9C-19C.
12. Fumaz CR, Tuldra A, Ferrer MJ et al. Quality of life, emotional status, and adherence of HIV-1 infected patients treated with efavirenz versus protease inhibitor containing regimen. J Acquir Immune Defic Syndr 2002; 29: 244-253.
13. Hawkins T, Geist C, Young B et al. Efavirenz induced CNS side effects persist for one year compared to protease inhibitors. 41st ICAAC. Chicago, IL, 2001 [Abstract I1725].
14. Ciesla JA, Roberts JE. Meta-analysis of relationship between HIV infection and risk for depressive disorders. Am J Psychiatr 2001; 158: 725-730.
15. Blanch J, Martinez E, Rousaud A et al. Preliminary data of a prospective study on neuropsychiatric side effects after initiation of efavirenz. J Acquir Immune Defic Syndr 2001; 27: 336-343.
16. Shafran S, Lefebvre E, Baril J et al. Retrospective analysis factors associated with discontinuation of efavirenz due to adverse effects. 1st IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires, Argentina. July 2001 [Abstract 537].
17. Marzolini C, Telenti A, Decosterd LA et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1 infected patients. AIDS 2001; 15: 71-75.
18. Nunez M, Gonzalez de Requena. D, Gallego L et al. Higher efavirenz plasma levels correlate with development of insomnia. J Acquir Immune Defic Syndr 2001; 28: 399-404.